



Dermatology Reports

<https://www.pagepress.org/journals/index.php/dr/index>

eISSN 2036-7406



SIDCO

Società Italiana di Dermatologia
Chirurgica, Oncologica, Correttiva ed Estetica

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. **Dermatology Reports** is, therefore, E-publishing PDF files of an early version of manuscripts that undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear on a regular issue of the journal. E-publishing of this PDF file has been approved by the authors.

Please cite this article as: D'Erme AM, Fidanzi C, Romanelli M, et al. COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports. Dermatol Rep 2023 [Epub Ahead of Print] doi: 10.4081/dr.2023.9763



© the Author(s), 2023
Licensee PAGEPress, Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports

Angelo Massimiliano D'Erme,¹ Cristian Fidanzi,² Marco Romanelli,² Velintina Dini,² Giovanni Bagnoni,¹ Agata Janowska²

¹Melanoma and Skin Cancer Unit AVNO (Area Vasta Nord Ovest) and Unit of Dermatology, Livorno Hospital, Livorno, Italy

²Unit of Dermatology, University of Pisa, Italy

Key words: “Chronic idiopathic urticaria”; “Chronic spontaneous urticaria”; “Omalizumab”; “COVID-19”; “Therapy”

Conflict of interest: None.

Funding source: None

Correspondence: Angelo Massimiliano D'Erme, Dermatology Unit, Livorno Hospital, and Melanoma & Skin Cancer Unit AVNO, Livorno, Italy

349-8451303 / a.m.derme@gmail.com

Author contribution:

- Study Conception and Design by AMD and AJ
- Data Analysis by CF, MR, GB and VD
- Literature Review/Study Results Interpretation by CF and VD
- Final Manuscript Draft/Editing by AJ and CF

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request

Dear Editor,

chronic spontaneous urticaria (CSU) is an inflammatory skin disease characterized by itchy pomphi associated or not with angioedema and occurring with daily or near-daily frequency for more than six weeks.¹ It is divided into two entities, an autoimmune form determined by the presence of IgG specific for FcεRI receptors on tissue mast cells and circulating basophils, and an idiopathic form.¹ It affects 0.5-1% of the world's population and has a major impact on patient's quality of life.¹ Several environmental factors can induce flare-ups, the most important of which include drugs (especially NSAIDs), infections, and foods.¹ To date, the first-line therapy is with a second-generation anti-H1 antihistamine at the standard dose; if there is no response after 2-4 weeks, you can increase the dosage to 4 times the standard dose. Treatment with systemic glucocorticoids is indicated only for short periods in severe flare-ups.¹ In case of therapeutic failure, in patients older than 12 years, it is possible to use an immunomodulating biological drug called omalizumab (OMZ), which is a humanized recombinant IgG1 monoclonal antibody able to bind and neutralize IgE but also to indirectly reduce the expression of the FcεRI receptor on tissue mast cells and circulating basophils.^{1,2} It is a safe medication with few side effects and can control the disease in many patients. Studies have shown that it does not increase the risk of Covid-19 or other airway infections.^{3,4} Current SARS-CoV-2 infection represents a major healthcare challenge, especially in managing patients with chronic disease. The impact and safety of biological treatment and the course of CSU during SARS-CoV-2 infection are poorly understood. We want to further clarify these aspects by reporting two cases of COVID-19 infection in patients with CSU treated with OMZ.

Case 1: A 22-year-old woman with a history of CSU for three years was treated with little success with an anti-H1 second-generation antihistamine (bilastine) with a dosage up to 4 times the standard. She does not suffer from other pathologies and, over the years, has made several cycles of therapy with systemic corticosteroid (deltacortene) with partial benefit; the symptoms, in fact, always relapsed when discontinued. Since antihistamines did not control the clinic, it was decided to start treatment with OMZ, an injection of 300 mg every four weeks. The score at baseline of urticaria activity over seven days (UAS7) was 26; this score reduced to 0 after only one month. After two months, the patient contacted us saying she had become COVID-19 positive and developed a paucisymptomatic form with moderate fever, pharyngodynia, ageusia, and anosmia. She had not had a COVID-19 vaccine. In agreement with the data already available in the literature,^{5,6} it is decided to continue with OMZ therapy. The family doctor prescribed the patient antibiotic coverage (azithromycin) and low-dose cortisone (betamethasone). Symptoms resolved within three days, and the patient never developed urticarial lesions. Four months after the resolution, she still maintains clinical remission.

Case 2: A 42-year-old man with seasonal allergic rhinoconjunctivitis and SCU for 1.5 years uncontrolled with second-generation anti-H1 antihistamine (loratadine) at four times the standard dosage and cycles of systemic corticosteroid (deltacortent), it was decided to start OMZ therapy with 300 mg injections every four weeks. The score at baseline of 7-day urticaria activity (UAS7) was 34; this score reduced to 0 after two months. Two months before OMZ initiation, the patient had double-dosed with the SARS-CoV-2 vaccine Comirnaty - BioNTech/Pfizer, when clinical worsening of UAS occurred. Despite the vaccination, three months after the first dose of OMZ, he contacted us reporting being positive for COVID-19 with the development of high fever, asthenia, cough, pharyngodynia, and headache. In this case, we decided to continue the therapy with OMZ. The patient took only paracetamol, and within five days, the symptoms completely resolved without the appearance of pomphoid lesions. At three months after the resolution, he still maintained clinical remission.

These two cases provide additional evidence to that already found in the literature on the safety of OMZ treatment in patients with mild-to-moderate COVID-19.^{5,6} Both of our patients did not experience worsening of the infection, which resolved within a few days. However, in patients with severe infection, given the few studies available, discontinuation of the drug or reduction in the frequency of injections is recommended, even but such a procedure could be wrong and

unnecessary, even in light of recent work that hypothesizes an even protective role of OMZ against COVID-19 disease.⁸

We would also like to point out that there was no exacerbation of pomphoid lesions during the infection. However, the literature reports a tendency to worsen the SCU during infection with COVID-19, especially in severe forms.⁹ This is probably attributable to the protective action of OMZ, which, if possible, should be maintained to ensure freedom from disease for the patient.

References

1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria [published online ahead of print, 2021 Sep 18]. *Allergy*. 2021;10.1111/all.15090. doi:10.1111/all.15090
2. Alizadeh Aghdam M, Knol EF, van den Elzen M, et al. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria. *Clin Exp Allergy*. 2020;50(3):364-371. doi:10.1111/cea.13566
3. Bostan E, Zaid F, Karaduman A, et al. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study. *J Cosmet Dermatol*. 2021;20(11):3369-3375. doi:10.1111/jocd.14484
4. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). *Clin Microbiol Infect*. 2018;24 Suppl 2:S21-S40. doi:10.1016/j.cmi.2018.02.002
5. Passante M, Napolitano M, Dastoli S, et al. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. *Dermatol Ther*. 2021;34(6):e15111. doi:10.1111/dth.15111
6. Criado PR, Criado RFJ, Pincelli TP, Yoshimoto TA, Naufal GGA, Abdalla BMZ. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab. *Int J Dermatol*. 2020;59(10):1294-1295. doi:10.1111/ijd.15134
7. Klimek L, Pfaar O, Worm M, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. *Allergol Select*. 2020;4:53-68. Published 2020 Sep 7. doi:10.5414/ALX02166E
8. Abdelmaksoud A, Goldust M, Vestita M. Omalizumab and COVID-19 treatment: Could it help?. *Dermatol Ther*. 2020;33(4):e13792. doi:10.1111/dth.13792

9. Kocatürk E, Salman A, Cherrez-Ojeda I, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. *Allergy*. 2021;76(3):816-830. doi:10.1111/all.14687